Physician profile
Daniel Juarez
NPI 1942303193
$13,544.73
in general payments reported to CMS, 2019-2025
48 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,173 · 2020: $2,228 · 2021: $2,811 · 2022: $1,552 · 2023: $1,032 · 2024: $1,395 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,780.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,920.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,705.14 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $1,353.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,096.60 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $563.88 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $473.67 | 2020-2025 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Esperion Therapeutics, INC. | $398.39 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.27 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $301.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $273.69 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $254.70 | 2019-2022 | |
| Abiomed | $200.60 | 2024 | Impella |
| Pfizer INC. | $180.06 | 2019-2025 | |
| Allergan, INC. | $178.17 | 2019-2020 | |
| Abbott Laboratories | $173.84 | 2021-2025 | Freestyle Libre 3 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $169.42 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $164.37 | 2020-2024 | |
| Endologix LLC | $145.34 | 2025 | Endocross Device, Torus Stent Graft System |
| Sunovion Pharmaceuticals INC. | $141.76 | 2021-2022 | |
| Radius Health, INC. | $140.34 | 2019 | |
| Amarin Pharma, INC. | $129.44 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.51 | 2023-2025 | Xifaxan |
| Antares Pharma, INC. | $106.94 | 2022 | |
| Exactech, INC. | $106.59 | 2019 | |
| Shield Therapeutics INC | $76.68 | 2024-2025 | |
| Corcept Therapeutics | $67.09 | 2024 | Korlym |
| Sanofi Pasteur INC. | $62.75 | 2021-2022 | |
| Atland Pharmaceuticals, LLC | $61.46 | 2024 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Nestle Healthcare Nutrition INC. | $60.08 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $56.93 | 2023 | Hetlioz, Fanapt |
| Abbvie INC. | $55.78 | 2022-2023 | |
| Lundbeck LLC | $54.30 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $49.36 | 2025 | Gvoke Hypopen |
| Boston Scientific Corporation | $47.39 | 2025 | Ams 700 |
| Kowa Pharmaceuticals America, INC. | $39.02 | 2020-2021 | |
| Circassia INC. | $33.57 | 2019 | |
| Sumitomo Pharma America, INC. | $30.61 | 2023 | Gemtesa |
| Dexcom, INC. | $29.41 | 2020-2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $28.51 | 2019 | |
| Vistapharm, INC. | $26.22 | 2021 | |
| Ani Pharmaceuticals, INC. | $25.82 | 2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $25.44 | 2019 | |
| Inspire Medical Systems, INC. | $20.68 | 2025 | Inspire |
| Bardy Diagnostics, INC. | $18.44 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.95 | 2023 | Quviviq |
| Biogen, INC. | $13.53 | 2023 | Skyclarys |
| Alexion Pharmaceuticals, INC. | $12.77 | 2020 | |
| Eisai INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Juarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.